| P50 | author | Francisco J Ramos | Q77833971 |
| | Maria Alsina | Q87300478 |
| P2093 | author name string | Alfredo Carrato | |
| | Josep Tabernero | |
| | Fernando Rivera | |
| | Jordi Giralt | |
| | Carlos López | |
| | Pilar García-Alfonso | |
| | Antonio Antón | |
| | Rafael López | |
| | Cristina Grávalos | |
| | Bernardo Queralt | |
| | Enrique Aranda | |
| | Maica Galán | |
| | Inmaculada Ruiz de Mena | |
| | José Enrique Alés-Martinez | |
| | Maria José Méndez-Vidal | |
| | Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR) | |
| P2860 | cites work | Cancer statistics, 2016 | Q29547383 |
| | Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 |
| | Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck | Q33371281 |
| | Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer | Q33377142 |
| | Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 |
| | Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival | Q33515519 |
| | Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. | Q34171999 |
| | EGFR and cancer prognosis | Q34399312 |
| | Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study | Q34471062 |
| | Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 |
| | Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction | Q34603020 |
| | Docetaxel in the treatment of esophageal cancer | Q36193625 |
| | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Q36892840 |
| | Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? | Q37325839 |
| | Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. | Q37449181 |
| | A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer | Q37481363 |
| | A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer | Q37608370 |
| | Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer | Q37832367 |
| | Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 |
| | Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial | Q38374359 |
| | Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. | Q38757690 |
| | Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. | Q39737918 |
| | Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. | Q40645806 |
| | Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha | Q41579755 |
| | Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer | Q43273409 |
| | Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. | Q44705891 |
| | A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer | Q44902236 |
| | Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation | Q45106730 |
| | Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer | Q57259796 |
| | A comparison of multimodal therapy and surgery for esophageal adenocarcinoma | Q71164736 |
| | Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis | Q74484559 |
| | Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome | Q79522451 |
| | Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06) | Q83128084 |
| | Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis | Q84371917 |
| | Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer | Q85031077 |
| | Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials | Q87088158 |
| P433 | issue | 1 | |
| P921 | main subject | cetuximab | Q420296 |
| | chemoradiotherapy | Q5090613 |
| P304 | page(s) | 69-78 | |
| P577 | publication date | 2018-02-01 | |
| P1433 | published in | Targeted oncology | Q25378200 |
| P1476 | title | A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients | |
| P478 | volume | 13 | |